TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03243500

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: per-caruncular peribulbar injection
Description: The patient will lie in a supine position and the eyes are in the neutral position. The needle (25 Gauge (G), 25 mm) insertion point will be just medial to the caruncle, directly perpendicular to the face and parallel to the medial orbital wall to 15-20 mm depth. After negative aspiration the already chosen local anesthetic mixture will be injected slowly. During injection, the globe will be palpated with one finger and tension in the lids will be tested frequently, if the lids become tense or if the tension is felt to rise in the globe, the injection will be stopped. After injection, external compression with Honan balloon inflated to 20-30 mm Hg will be applied for 10 minutes and will be removed every 2 minutes to test akinesia and anesthesia
Study: NCT04312282

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tesetaxel
Description: Tesetaxel orally on Day 1 of a 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tesetaxel
Description: Tesetaxel orally on Day 1 of a 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tesetaxel
Description: Tesetaxel orally on Day 1 of a 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Itraconazole orally once daily from Day -3 to Day 14 of a 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: Rifampin orally once daily from Day -6 to Day 14 of a 21-day cycle
Study: NCT00568256

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mind/Body Courses
Description: 8-week Mind/Body course held once a week for 2 hours at a time.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Mind/Body Courses
Description: 8-week Mind/Body course held once a week for 2 hours at a time.
Study: NCT03946670

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBG453
Description: MBG453 is being administered i.v.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is being administered i.v.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypomethylating agents
Description: Decitabine is being administered i.v. Azacitidine is being administered i.v or s.c.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hypomethylating agents
Description: Decitabine is being administered i.v. Azacitidine is being administered i.v or s.c.
Study: NCT03283917

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given IV or PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: Given PO
Study: NCT03329248

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALT-803
Description: Recombinant human super agonist interleukin-15 (IL-15) complex

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETBX-011
Description: Ad5 \[E1-, E2b-\]-CEA
Study: NCT02506881

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa
Study: NCT03329248

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GI-4000
Description: Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant Ras proteins

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: haNK for infusion
Description: NK-92 \[CD16.158V, ER IL-2\]

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: avelumab
Description: Recombinant human anti-PD-L1 IgG1 monoclonal antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Recombinant human anti-VEGF IgG1 monoclonal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: 5-fluoro-2,4 (1H,3H)-pyrimidinedione
Study: NCT03329248

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: L-Glutamic acid, N-\[4-\[\[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl\]amino\]benzoyl\]-, calcium salt

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-Paclitaxel
Description: Benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-(2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4,11-dihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca\[3,4\]benz\[1,2-b\]oxet-9-y1ester,(αR,βS)-(9CI) bound to albumin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lovaza
Description: Omega-3-acid ethyl esters

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: cis-\[(1 R,2 R)-1,2-cyclohexanediamine-N,N'\] \[oxalato(2-)- O,O'\] platinum

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SBRT
Description: Stereotactic Body Radiation Therapy
Study: NCT01921738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1% Azithromycin gel
Description: Participants received mechanical periodontal therapy, oral hygiene instructions and placement of the in-situ gel (0.2 ml 1% Azithromycin) into the periodontal pockets in single rooted teeth; twice with an interval of 20 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Participants received mechanical periodontal therapy, oral hygiene instructions and antibiotic (Azithromycin 250mg x 6 capsules)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo gel
Description: Participants received mechanical periodontal therapy, oral hygiene instructions and placebo (antibiotic) in situ gel.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo capsule
Description: Participants received mechanical periodontal therapy (Scaling and Root Planing), oral hygiene instructions and placebo (antibiotic) capsules (250mg x 6), at mouth (Po), two times a day (bid) for three days.
Study: NCT03535194

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirikizumab
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirikizumab
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirikizumab
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirikizumab
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered SC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Secukinumab
Description: Administered SC
Study: NCT04820231

Intervention type: OTHER
Group type: OTHER
Intervention: intra-articular PRP injection
Study: NCT01679912

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: phone to the call center
Description: recommendations to phone to the call center for all the patients who have an acute attack
Study: NCT02506881

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa
Study: NCT02787759

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hands-Free Walking
Description: Walking on a treadmill at 60-80% maximum heart rate without holding onto anything

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Challenge Based plus Hands-Free'
Description: Walking on a treadmill at 60-80% maximum heart rate without holding onto anything under 9 different challenging conditions
Study: NCT01764698

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CALM-SUD
Description: 6-session group for anxiety disorders. Cognitive behavioral therapy including self-monitoring, relaxation, cognitive restructuring, exposure therapy, and relapse prevention. In addition, participants in this arm are also enrolled in an Intensive Outpatient Program for their substance use disorder. The program is run by an outpatient addictions facility and includes up to 16 weeks of groups that meet 3 to 4 times per week in addition to up to 10 individual sessions of therapy. The group model includes motivational interviewing, cognitive behavioral therapy, contingency management, and relapse prevention skills.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: The program is run by an outpatient addictions facility and includes up to 16 weeks of groups that meet 3 to 4 times per week in addition to up to 10 individual sessions of therapy. The group model includes motivational interviewing, cognitive behavioral therapy, contingency management, and relapse prevention skills.
Study: NCT01938898

Intervention type: OTHER
Group type: OTHER
Intervention: Invitation letter randomisation
Description: There are 12 versions of the invitation letter. Three aspects of the letter will be adapted: (1) Gender of the signatory i.e. male, female or gender neutral (signed from the NICOLA team) (2) Description of NICOLA as a 'study' or 'project' and (3) Inserting a sentence guaranteeing the participants confidentially or not having this in the letter (but will still appear in the Patient Information Sheet). The twelve versions are as follows:~1. Male \& Study \& Confidentiality~2. Male \& Study~3. Male \& Project \& Confidentiality~4. Male \& Project~5. Female \& Project \& Confidentiality~6. Female \& Project~7. Female \& Study \& Confidentiality~8. Female \& Study~9. Neutral \& Study \& Confidentiality~10. Neutral \& Study~11. Neutral \& Project \& Confidentiality~12. Neutral \& Project
Study: NCT01351883

Intervention type: DIETARY_SUPPLEMENT
Group type: NO_INTERVENTION
Intervention: ANOM
Description: the ANOM was given 800ml per day before operation, and added from POD2 to POD 14 gradually from 400ml to 1200ml
Study: NCT01359722

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Description: N-acetylcysteine is administered at a dose of 150mg/kg in 500mL of saline EV in 1 hour followed by a dose of 50mg/kg in 500 mL of saline IV within 6 hours, beginning the infusion together to surgery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: The control group will receive only the infusion of saline in the same doses and infusion rate.
Study: NCT03847480

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: FDG-PET guided dose painting
Description: The radiation dose inside the gross tumor volume is increased according to the voxel intensity (SUV - standardized uptake value) of pre-treatment FDG PET.
Study: NCT00944892

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN475
Description: 2 Administrations of REGN475 within 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN475
Description: 2 Administrations of REGN475 within 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN475
Description: 2 Administrations of REGN475 within 24 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match REGN475 doses
Study: NCT01293383

Intervention type: DRUG
Group type: OTHER
Intervention: LEO 90105
Description: Ointment

Intervention type: DRUG
Group type: OTHER
Intervention: LEO 90105
Description: Ointment
Study: NCT00762645

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travoprost 0.004% (Travatan)
Description: One drop in each eye, once daily at 9 AM

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pilocarpine 1%
Description: One drop in each eye, forth times daily at 7 AM, 11 AM , 4 PM and 9 PM for twelve (12) weeks
Study: NCT02915562

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercise

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercise
Study: NCT01620307

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sirolimus (Rapamune 2mg/day, Pfizer)
Description: Sirolimus (Rapamune 2mg/day, Pfizer) or not for a course of 14 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus (Rapamune 2mg/day, Pfizer)
Description: Sirolimus (Rapamune 2mg/day, Pfizer) or not for a course of 14 days.
Study: NCT04885426

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: low-dose metformin
Description: Metformin Pill 250mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: high-dose metformin
Description: Metformin Pill 500mg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03075098

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Digital colposcope
Description: Diagnostic accuracy of colposcopic examination; Swede scoring system will be used to evaluate the colposcopic examination. Then, the specificity (%) and the sensitivity (%) of colposcopic examination will be calculated using the cutoff value of 8 to segregate dysplastic from non-dysplastic lesions.
Study: NCT02896101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimecrolimus Cream, 1%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Elidel® (pimecrolimus) Cream

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of Pimecrolimus Cream, 1%
Study: NCT01215032

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Taken orally twice daily each 28-day cycle, for 12 cycles
Study: NCT02041312

Intervention type: OTHER
Intervention: No intervention
Description: No intervention will be needed.
Study: NCT04459221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gardasil 9, 9-Valent Intramuscular Suspension
Description: access to HPV vaccination near the college in a health bus
Study: NCT00983892

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caregiver website
Description: Website receives patient symptom assessment data from IVR and provides caregivers with weekly updates on patient status, allowing caregivers to access tailored symptom management advice and formulate an action plan.
Study: NCT03618706

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Involved-field radiotherapy
Description: After the diagnosis of recurrences, patients will receive involved-field radiotherapy (gross tumor volume + margin) with any radiation dose scheme (≥45 Gy Biological Equivalent dose) as physician's discretion.
Study: NCT03020056

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Phacolin eye drops
Description: After enrollment, the participants will be provided antioxidant eye drops, Phacolin (Zhongshan ophthalmic center, China) for free.The eye drops will be administered 4 times per day for 1 year.Then either phacoemulsification or manual small incision cataract surgery will be performed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cataract surgery
Description: After enrollment,either phacoemulsification or manual small incision cataract surgery will be performed within 4 weeks.
Study: NCT01588210

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sealant application
Description: A high-viscosity glass-ionomer cement (KETAC™ MOLAR APLICAP 3M Espe, Germany) will be used.~All sealants was applied following these steps: tooth isolation using cotton rolls or rubber dam; tooth cleaning using a rotary brush mounted on a low-speed contrangle with a prophylaxis pasta without fluoride; enamel etching using 37% phosphoric acid (H3PO4) for 30 seconds; rinse thoroughly with water and dry; placement a thin layer of sealant material and cure according to manufacturer's instructions and finally occlusion adjustment, if necessary.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sealant application
Description: A white photopolymerizable Resin-Based sealant containing fluoride (Helioseal F®, Ivoclar Vivadent AG, Fürstentum Liechtenstein) will be used.~All sealants was applied following these steps: tooth isolation using cotton rolls or rubber dam (it was mandatory for both the RB sealants); tooth cleaning using a rotary brush mounted on a low-speed contrangle with a prophylaxis pasta without fluoride; enamel etching using 37% phosphoric acid (H3PO4) for 30 seconds; rinse thoroughly with water and dry; placement a thin layer of sealant material and cure according to manufacturer's instructions and finally occlusion adjustment, if necessary.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: sealant application
Description: A white photopolymerizable Resin-Based sealant (Concise 1930TM 3M Espe, Germany) will be used.~All sealants was applied following these steps: tooth isolation using cotton rolls or rubber dam (it was mandatory for both the RB sealants); tooth cleaning using a rotary brush mounted on a low-speed contrangle with a prophylaxis pasta without fluoride; enamel etching using 37% phosphoric acid (H3PO4) for 30 seconds; rinse thoroughly with water and dry; placement a thin layer of sealant material and cure according to manufacturer's instructions and finally occlusion adjustment, if necessary.
Study: NCT01674803

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Orsiro
Description: biodegradable polymer sirolimus eluting stent

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Synergy
Description: biodegradable polymer everolimus eluting stent

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Resolute Integrity
Description: durable polymer zotarolimus-eluting stent
Study: NCT02736955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valbenazine
Study: NCT01665599

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone gel (FE 999303)
Study: NCT00357318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib malate
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01187147

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: green tea extract
Description: Green tea extract capsule, equivalent to 450 ml 2% Green tea containing 540mg EGCG/day
Study: NCT03653091

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Duodenal Mucosal Resurfacing (DMR)
Description: The Fractyl DMR procedure utilizes the Revita™ Catheter to perform hydrothermal ablation of the duodenum. The catheter is delivered trans-orally over a guide-wire to first inject saline to lift the sub-mucosal space, followed by an ablation of the duodenal mucosa. Subjects who receive the DRM treatment are followed for 48 weeks while Sham subjects who cross over and undergo the DMR procedure at 24 weeks are followed for further 24 weeks post treatment. Sham subjects who choose not to cross over are discontinued from the study.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Duodenal Mucosal Resurfacing Sham (Sham)
Description: The Sham procedure consists of placing the Revita™ Catheter as described above into the duodenum for a minimum of 30 minutes and then removing it from the patient.
Study: NCT02710344

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telehealth Program
Description: Psychiatric telehealth program, content assigned based on diagnosis, entry to study requires psychiatric instability defined as use of emergency/high cost psychiatric services.
Study: NCT02083679

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 1: Sym004 6 mg/kg + Cisplatin/Gemcitabine
Description: Sym004 will be administered as an intravenous infusion at a dose of 6 mg/kg weekly until unacceptable toxicity, progressive disease, withdrawal of consent, or until the subject meets any of the criteria for subject withdrawal, or withdrawal from the investigational medicinal product (IMP) in combination with platinum-doublet chemotherapy regimen of cisplatin/gemcitabine (cisplatin 75 mg/m\^2 on Day 1 plus gemcitabine 1250 mg/m\^2 on Days 1 and 8 of every 3-Week cycle intravenously for a maximum of 6 treatment cycles).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 1: Sym004 6 mg/kg + Cisplatin/Pemetrexed
Description: Sym004 will be administered as an intravenous infusion at a dose 6 mg/kg weekly until unacceptable toxicity, progressive disease, withdrawal of consent, or until the subject meets any of the criteria for subject withdrawal, or withdrawal from the IMP in combination with platinum-doublet chemotherapy regimen of cisplatin/pemetrexed (cisplatin 75 mg/m\^2 plus pemetrexed 500 mg/m\^2 on Day 1 of every 3-Week cycle intravenously for a maximum of 6 treatment cycles).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 1: Sym004 6 mg/kg + Carboplatin/Paclitaxel
Description: Sym004 will be administered as an intravenous infusion at a dose 6 mg/kg weekly until unacceptable toxicity, progressive disease, withdrawal of consent, or until the subject meets any of the criteria for subject withdrawal, or withdrawal from the IMP in combination with platinum-doublet chemotherapy regimen of carboplatin/paclitaxel (carboplatin area under the concentration-time curve (AUC) = 6 milligram per millilitre per minute \[mg/mL/min\] plus paclitaxel 225 mg/m\^2 on Day 1 of 3-Week cycle intravenously for a maximum of 6 treatment cycles).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 1: Sym004 6/12 mg/kg + Carboplatin/Paclitaxel
Description: Sym004 will be administered as an intravenous infusion at a dose 6 mg/kg on Day 1 and 12 mg/kg on Day 8 of a 3-Week cycle until unacceptable toxicity, progressive disease, withdrawal of consent, or until the subject meets any of the criteria for subject withdrawal, or withdrawal from the IMP in combination with platinum-doublet chemotherapy regimen of carboplatin/paclitaxel (carboplatin AUC = 6 mg/mL/min plus paclitaxel 225 mg/m\^2 on Day 1 of every 3-Week cycle intravenously for a maximum of 6 treatment cycles).
Study: NCT02257918

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0914
Description: AZD0914 is an antimicrobial amorphous nonsterile powder. Group 1 receive 2000 mg; Group 2 receive 3000 mg. The drug name is also known as ETX0914.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0914
Description: AZD0914 is an antimicrobial amorphous nonsterile powder. Group 1 receive 2000 mg; Group 2 receive 3000 mg. The drug name is also known as ETX0914.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ceftriaxone
Description: Ceftriaxone is a broad-spectrum cephalosporin antibiotic with a very long half-life and high penetrability to meninges, eyes and inner ears. A white to yellowish orange crystalline powder. Group 3 receives 500 mg reconstituted with 1 ml Lidocaine HCL 1%, intramuscularly.
Study: NCT05402618

Intervention type: OTHER
Intervention: No intervention
Description: This is an observational study without any intervention.

Intervention type: OTHER
Intervention: No intervention
Description: This is an observational study without any intervention.